Condition 1: Myocardial Infarction. Condition 2: Type 2 diabetes. Acute transmural myocardial infarction of unspecified site Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention 1: Intervention group: In this group, 30 type 2 diabetic patients treated with oral drugs, and they will receive empagliflozin from ABIDI Pharmaceutical Company in the form of 10 mg table
Sponsors
Zanjan University of Medical Sciences
Abidi Pharmaceutical Company
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetic patients (Hb A1C: 6.5-8) Diabetes treated with oral agents Typical chest pain during the 12 hours before presentation lasting more than 30 minutes ST- segment elevation above 0.1 mV in two leads or more in ECG
Exclusion criteria
Exclusion criteria: Cardiogenic shock Diabetic ketoacidosis History of CABG Type 1 diabetic patients Severe liver failure End stages cancer or history of any cancer History of severe allergy to empagliflozin or its formulation components Severe renal failure (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis Hypovolemia Any inflammatory disease under treatment Advanced heart failure Hypoglycemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Galectin-3 gene expression. Timepoint: Measurement of Galectin-3 gene expression at the beginning of the study (before intervention) and 3 months after starting empagliflozin. Method of measurement: RT-PCR.;SST2 gene expression. Timepoint: Measurement of sST2 gene expression at the beginning of the study (before intervention) and 3 months after starting empagliflozin. Method of measurement: RT-PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahnaz Yousefi Ramandi
Zanjan University of Medical Sciences
Outcome results
None listed